Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics

Archives of Neurology

Volumn 56, Issue 9, 1999, Pages 1079-1084

  Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NEUTRALIZING ANTIBODY; PLACEBO;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART PALPITATION; HOUSEHOLD; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PHYSICAL DISABILITY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; WALKING; WORK DISABILITY;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PATIENT SELECTION; PEPTIDES; RECOMBINANT PROTEINS;

EID: 0032887108     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.9.1079     Document Type: Review

References (49)

1. Whetten-Goldstein KFA, Sloan L, Goldstein B, Kulas B. A comprehensive assessment of cost and compensation: the case of multiple sclerosis. Mult Scler. 1998; 4:419-425.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
3. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med. 1997;337:1604-1611.
4. Jacobs L, Cookfair DL, Rudick RA, et al, for the Multiple Sclerosis Collaborative Research Group. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler. 1995;1:118-135.
5. Jacobs LD, Cookfair DL, Rudick RA, et al, for the Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
6. Paly DW, Li DK, for the University of British Columbia MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
7. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:656-661.
9. Johnson KP, Brooks BR, Cohen JA, et al, for the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45:1268-1276.
10. Johnson KP, Brooks BR, Cohen JA, et al, for the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50:701-708.
11. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 1996;47:889-894.
12. Rudick RA, Simonian NA, Alam JA, et al, for the Multiple Sclerosis Collaborative Research Group. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 1998;50:1266-1272.
13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
14. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
15. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
17. Rudick RA, Goodkin DE, Jacobs LD, et al, for the Multiple Sclerosis Collaborative Research Group. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology. 1997;49:358-363.
18. Stone LA, Frank JA, Albert PS, et al. The effect of interteron-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
19. Simon JH, Jacobs LD, Campion M, et al, for the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 1998;43:79-87.
20. β-1a) for relapsing multiple sclerosis. J Neuroimmunol. 1999;93:8-14.
21. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:682-689.
22. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996;67:111-118.
23. Lu HT, Riley JL, Babcock GT, et al. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kd DNA-binding protein, ISGF3-gamma. J Exp Med. 1995;182:1517-1525.
24. Leppert D, Waubant E, Burk MR, Oksenbert JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40: 846-852.
25. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996; 40:853-863.
26. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol. 1997;41:669-674.
27. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998;50:1294-1300.
28. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993;46: 145-153.
29. Cohen JA, Grossman RI, Udupa JK, et al. Assessment of the efficacy of copolymer-1 in the treatment of multiple sclerosis by quantitative MRI [abstract]. Neurology. 1995;45:A418.
30. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology. 1998; 50:1127-1133.
31. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med. 1996;183:1777-1788.
32. Tuohy V, Yu M, Weinstock-Guttman B, Kinkel R. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest. 1997; 99:1682-1690.
33. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson. 1997; 7:29-37.
34. McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198-205.
35. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992;32:758-766.
36. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Work S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
37. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44:635-641.
38. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology. 1996;47:123-129.
39. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology. 1994;44:1537-1540.
40. β-1b: the use of an assay for neutralizing antibodies. Neurology. 1996;47:865-866.
41. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
42. Goodkin D, Rudick R, Medendorp S, Greene T. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis: design of a randomized, placebo-controlled trial with sample-size benefits from a composite outcome variable including preliminary data on toxicity. J Online Curr Clin Trials. September 25, 1992; document 19. Online journal no longer exists.
43. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995;1:37-47.
44. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996;40:469-479.
45. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997;42:379-382.
46. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
47. Simon JH, Jacobs LD, Campion M, Rudick RA. A longitudinal study of brain atrophy in relapsing MS. Neurology. 1999;53:139-148.
48. Rudick RA, Goodman AD, Herndon RM, Panitch HS. Selecting relapsing remitting MS patients for treatment: the case for early treatment. J Neuroimmunol. In press.
49. Lucchinetti C, Bruck W, Rodriquez M, Lassmann H. Distinct pattern of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 1996; 6:259-274.